Patents by Inventor Cornelia Dorner-Ciossek

Cornelia Dorner-Ciossek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110015193
    Abstract: The invention relates to novel substituted pyrazolopyrimidines. Chemically, the compounds are characterised by general Formula (I): with R1 being phenyl or pyridyl, any of which is substituted with 1 to 4, preferably 1 to 3 substituents X; X independently of each other being selected from C2-C6-alky1 or Ci-C6-alkoxy, where C2-C6-alkyl and C1-C6-alkoxy are at least dihalogenated up to perhalogenated. preferably with 2 to 6 halogen substituents, and the halogen atoms being selected from the group of fluoro, chloro and bromo, preferably fluoro; R2 being phenyl or heteroaryl, where phenyl is substituted by 1 to 3 radicals and heteroaryl is optionally substituted by 1 to 3 radicals in each case independently of one another selected from the group of C1-C6-alkyI, C1-C6-alkoxy, hydroxycarbonyl, cyano, trifluoromethyl, amino, nitro, hydroxy, C1-C6-alkylamino, halogen, C6-C10-arylcarbonylamino, C1-C6-alkylcarbonylamino, C1-C6-alkylaminocarbonyl. C1-C6-alkoxycarbonyl, C6-C10-arylaminocarbonyl, heteroarylaminocarbonyl.
    Type: Application
    Filed: November 27, 2008
    Publication date: January 20, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Christian Eickmeier, Cornelia Dorner-Ciossek, Dennis Fiegen, Thomas Fox, Klaus Fuchs, Riccardo Giovannini, Niklas Heine, Martin Hendrix, Holger Rosenbrock, Gerhard Schaenzle
  • Publication number: 20100298278
    Abstract: The invention relates to the substituted 1,2-ethylenediamines of general formula (I), wherein the groups R1 to R13, A, B, L and i are defined as in the description and the claims. The invention also relates to the use thereof in the treatment of Alzheimer's disease (AD) and similar diseases.
    Type: Application
    Filed: August 8, 2006
    Publication date: November 25, 2010
    Inventors: Christian Eickmeier, Klaus Fuchs, Niklas Heine, Stefan Peters, Cornelia Dorner-Ciossek, Sandra Handschuh, Herbert Nar, Klaus Klinder
  • Publication number: 20100249158
    Abstract: The present invention relates to substituted amino-quinazolinones of general formula (I) wherein the groups R1 to R14 and A, are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.
    Type: Application
    Filed: July 3, 2008
    Publication date: September 30, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Klaus Fuchs, Niklas Heine, Christian Eickmeier, Sandra Handschuh, Cornelia Dorner-Ciossek, Stefan Hoerer
  • Publication number: 20100204160
    Abstract: The present invention relates to substituted 1,2-ethylenediamines of general formula (I) wherein the groups R1 to R15, A, B, L, i as well as X1-X4 are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.
    Type: Application
    Filed: April 13, 2010
    Publication date: August 12, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Christian EICKMEIER, Stefan PETERS, Klaus FUCHS, Niklas HEINE, Sandra HANDSCHUH, Cornelia DORNER-CIOSSEK, Klaus KLINDER, Marcus KOSTKA
  • Publication number: 20100168070
    Abstract: The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the radicals R1-R13, A, B, L and i are as defined in the description and in the claims. The invention also relates to the use thereof for treating Alzheimer's disease (AD) and similar diseases.
    Type: Application
    Filed: August 8, 2006
    Publication date: July 1, 2010
    Inventors: Niklas Heine, Klaus Fuchs, Christian Eickmeier, Stefan Peters, Cornelia Dorner-Ciossek, Sandra Handschuh, Herbert Nar, Klaus Klinder
  • Publication number: 20100144681
    Abstract: The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the radicals R1-R13, A, B, L and i are as defined in the description and the claims. The invention also relates to the use thereof for treating Alzheimer's disease (AD) and similar diseases.
    Type: Application
    Filed: August 8, 2006
    Publication date: June 10, 2010
    Inventors: Klaus Fuchs, Christian Eickmeier, Niklas Heine, Stefan Peters, Cornelia Dorner-Ciossek, Sandra Handschuh, Herbert Nar, Klaus Klinder
  • Patent number: 7713961
    Abstract: The present invention relates to substituted 1,2-ethylenediamines of general formula (I) wherein the groups R1 to R15, A, B, L, i as well as X1—X4 are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.
    Type: Grant
    Filed: March 30, 2006
    Date of Patent: May 11, 2010
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christian Eickmeier, Stefan Peters, Klaus Fuchs, Niklas Heine, Sandra Handschuh, Cornelia Dorner-Ciossek, Klaus Klinder, Marcus Kostka
  • Publication number: 20090325940
    Abstract: The present invention relates to substituted 1,2-ethylenediamines of general formula (I) wherein the groups R1 to R15, A, B, L, i as well as X1-X4 are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.
    Type: Application
    Filed: July 29, 2009
    Publication date: December 31, 2009
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Christian Eickmeier, Stefan Peters, Klaus Fuchs, Niklas Heine, Sandra Handschuh, Cornelia Dorner-Ciossek, Klaus Klinder, Marcus Kostka
  • Patent number: 7534787
    Abstract: A method of treating or preventing of a disease or condition associated with an increased level of isoforms of amyloid ? peptides (A?) and/or with a changed ratio of levels of A? isoforms and/or with the formation of plaques containing amyloid ? peptide (A?) isoforms in a mammal comprising administering to said mammal an therapeutically effective amount of a compound selected from the formulas Ia, Ib wherein V, W, Y, R2, R3, R5, R6, L1 and i are defined as in claim 1.
    Type: Grant
    Filed: January 17, 2008
    Date of Patent: May 19, 2009
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Bornemann, Guenter Trummlitz, Bernd Beck, Frank Sams-Dodd, Dagmar Kugler, Klaus Klinder, Cornelia Dorner-Ciossek, Marcus Kostka
  • Publication number: 20090099159
    Abstract: A method of treating or preventing of a disease or condition associated with an increased level of isoforms of amyloid ? peptides (A?) and/or with a changed ratio of levels of A? isoforms and/or with the formation of plaques containing amyloid ? peptide (A?) isoforms in a mammal comprising administering to said mammal an therapeutically effective amount of a compound selected from the formulas Ia, Ib wherein V, W, Y, R2, R3, R5, R6, L1 and i are defined as in claim 1.
    Type: Application
    Filed: December 17, 2008
    Publication date: April 16, 2009
    Applicants: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
    Inventors: Klaus BORNEMANN, Guenter TRUMMLITZ, Bernd BECK, Frank SAMS-DODD, Dagmar KUGLER, Klaus KLINDER, Cornelia DORNER-CIOSSEK, Marcus KOSTKA
  • Publication number: 20090042867
    Abstract: The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the radicals R1 to R13, A, B, L, and i are defined as indicated in the description and the claims, as well as the use thereof for treating Alzheimer's disease (AD) and similar diseases.
    Type: Application
    Filed: August 8, 2006
    Publication date: February 12, 2009
    Inventors: Klaus Fuchs, Christian Eickmeier, Niklas Heine, Stefan Peters, Cornelia Dorner-Ciossek, Sandra Handschuh, Herbert Nar, Klaus Klinder
  • Publication number: 20080293680
    Abstract: The invention relates to a compound of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and R8 are defined as in the specification and claims and to its use for treating or preventing Alzheimer's disease and other similar diseases.
    Type: Application
    Filed: August 1, 2006
    Publication date: November 27, 2008
    Inventors: Stefan Peters, Christian Eickmeier, Klaus Fuchs, Werner Stransky, Cornelia Dorner-Ciossek, Marcus Kostka, Sandra Handschuh, Herbert Nar, Klaus Bornemann, Klaus Klinder, Margit Bauer
  • Publication number: 20080139541
    Abstract: A method of treating or preventing of a disease or condition associated with an increased level of isoforms of amyloid ? peptides (A?) and/or with a changed ratio of levels of A? isoforms and/or with the formation of plaques containing amyloid D peptide (A?) isoforms in a mammal comprising administering to said mammal an therapeutically effective amount of a compound selected from the formulas Ia, Ib wherein V, W, Y, R2, R3, R5, R6, L1 and i are defined as in claim 1.
    Type: Application
    Filed: January 17, 2008
    Publication date: June 12, 2008
    Inventors: Klaus Bornemann, Guenter Trummlitz, Bernd Beck, Frank Sams-Dodd, Dagmar Kugler, Klaus Klinder, Cornelia Dorner-Ciossek, Marcus Kostka
  • Patent number: 7375220
    Abstract: A method of treating or preventing of a disease or condition associated with an increased level of isoforms of amyloid ? peptides (A?) and/or with a changed ratio of levels of A? isoforms and/or with the formation of plaques containing amyloid ? peptide (A?) isoforms in a mammal comprising administering to said mammal an therapeutically effective amount of a compound selected from the formulas Ia, Ib wherein V, W, Y, R2, R3, R5, R6, L1 and i are defined as in claim 1.
    Type: Grant
    Filed: May 19, 2005
    Date of Patent: May 20, 2008
    Assignees: Boehringer Ingelheim Vetmedica GmbH, Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Klaus Bornemann, Guenter Trummlitz, Edward S. Lazer, Clara K. Miao, Bernd Beck, Frank Sams-Dodd, Dagmar Kugler, Klaus Klinder, Cornelia Dorner-Ciossek, Marcus Kostka
  • Patent number: 7238774
    Abstract: The invention relates to a compound of the formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and R8 are defined as in the specification and claims and to its use for treating or preventing Alzheimer's disease and other similar diseases.
    Type: Grant
    Filed: November 7, 2005
    Date of Patent: July 3, 2007
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Stefan Peters, Klaus Fuchs, Christian Eickmeier, Werner Stransky, Cornelia Dorner-Ciossek, Sandra Handschuh, Herbert Nar, Klaus Klinder, Marcus Kostka
  • Patent number: 7166599
    Abstract: The present invention relates to trisubstituted pyrimidines of formula wherein Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses in which ?-amyloid modulators have a therapeutic benefit, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
    Type: Grant
    Filed: December 9, 2004
    Date of Patent: January 23, 2007
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Klaus Bornemann, Hans Briem, Cornelia Dorner-Ciossek, Katja Fechteler, Klaus Fuchs, Frank Himmelsbach, Klaus Klinder, Markus Kostka
  • Publication number: 20060223759
    Abstract: The present invention relates to substituted 1,2-ethylenediamines of general formula (I) wherein the groups R1 to R15, A, B, L, i as well as X1-X4 are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.
    Type: Application
    Filed: March 30, 2006
    Publication date: October 5, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Christian Eickmeier, Stefan Peters, Klaus Fuchs, Niklas Heine, Sandra Handschuh, Cornelia Dorner-Ciossek, Klaus Klinder, Marcus Kostka
  • Publication number: 20060160747
    Abstract: The invention relates to a compound of the formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined as in the specification and claims and to its use for treating or preventing Alzheimer's disease and other similar diseases.
    Type: Application
    Filed: November 7, 2005
    Publication date: July 20, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Stefan Peters, Klaus Fuchs, Christian Eickmeier, Werner Stransky, Cornelia Dorner-Ciossek, Sandra Handschuh, Herbert Nar, Klaus Klinder, Marcus Kostka
  • Publication number: 20060100158
    Abstract: The invention relates to a compound of the formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and R8 are defined as in the specification and claims and to its use for treating or preventing Alzheimer's disease and other similar diseases.
    Type: Application
    Filed: November 7, 2005
    Publication date: May 11, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Stefan Peters, Klaus Fuchs, Christian Eickmeier, Werner Stransky, Cornelia Dorner-Ciossek, Sandra Handschuh, Herbert Nar, Klaus Klinder, Marcus Kostka
  • Publication number: 20060040928
    Abstract: A method of treating or preventing of a disease or condition associated with an increased level of isoforms of amyloid ? peptides (A?) and/or with a changed ratio of levels of A? isoforms and/or with the formation of plaques containing amyloid ? peptide (A?) isoforms in a mammal comprising administering to said mammal an therapeutically effective amount of a compound selected from the formulas Ia, Ib wherein V, W, Y, R2, R3, R5, R6, L1 and i are defined as in claim 1.
    Type: Application
    Filed: May 19, 2005
    Publication date: February 23, 2006
    Applicants: Boehringer Ingelheim Vetmedica GmbH, Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Klaus Bornemann, Guenter Trummlitz, Edward Lazer, Clara Miao, Bernd Beck, Frank Sams-Dodd, Dagmar Kugler, Klaus Klinder, Cornelia Dorner-Ciossek, Marcus Kostka